Breaking News Headlines Today

News about GLP-1

Stay current with all the latest and breaking news about GLP-1, compare headlines and perspectives between news sources on stories happening today. In total, 278 stories have been published about GLP-1 which Ground News has aggregated in the past 3 months.

Covered Most By

Anti-Aging, Acupuncture and Health News

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top GLP-1 News

GLP-1 · Austin

Study: 82% Regain Weight After Stopping Mounjaro

45% Center coverage: 9 sources

See the Story

GLP-1 · Canton

GLP-1 Discontinuation Associated with More Weight Gain and Pregnancy Complications

78% Center coverage: 9 sources

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.See the Story

Novo Nordisk · United States

Medicare negotiates 71% discount on Novo’s Ozempic, Wegovy

60% Center coverage: 5 sources

The U.S. government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S’s blockbuster drugs Ozempic and Wegovy for patients in Medicare, the federal health insurance program for the elderly. Read more...See the Story

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PressReach

BEIJING, Nov. 27, 2025 /PRNewswire/ — Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore i…GLP-1 · China Read Article

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.Diabetes See the Story

Increasing semaglutide dose showed very unexpected weight loss results in trials

100% Center coverage: 1 sources

A higher dose of semaglutide achieves a 19% loss in body weight and redefines the limits of obesity treatment.GLP-1 Read Article

Is Chronic Cough Another Side Effect of GLP-1 Drugs?

Coverage: 2 sources

(MedPage Today) -- GLP-1 receptor agonist use was associated with chronic cough regardless of a previous gastroesophageal reflux disease (GERD) diagnosis, a study of over 2 million people with type 2 diabetes suggested. Adults prescribed a GLP...GLP-1 See the Story

After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer

MEXICO- In a press release published on the Novo Nordisk website on 24 November, the results of the “phase 3 evoke and evoke+ trials in early symptomatic Alzheimer’s” of his medicine known as Ozempic were released randomly, with a total of 3,808 adults for the purpose of evaluating “the efficacy and safety of oral semaglutide compared to placebo, in addition to the standard of care”, explains Novo Nordisk and continues explaining that “the decis…Alzheimer's Disease · San Diego See the Story

Questions on how new IRA drug prices will affect MFN agreements - Pharmaceutical Technology

The second round of IRA negotiations brings the total number of negotiated drugs to 25.Drug Prices · Washington See the Story

2025 dominates for GLP-1 trial activity

Stronger funding and investment, fewer cancellations and faster study starts have supported the expansion of trial numbers.The post 2025 dominates for GLP-1 trial activity appeared first on Clinical Trials Arena.GLP-1 Read Article

News about GLP-1

News about GLP-1

Covered Most By

Local News Publishers

Top GLP-1 News

Study: 82% Regain Weight After Stopping Mounjaro

GLP-1 Discontinuation Associated with More Weight Gain and Pregnancy Complications

Medicare negotiates 71% discount on Novo’s Ozempic, Wegovy

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PressReach

Use of Glp-1 Ras Before Pregnancy Increases the Complication Rate.

Drugs like Ozempic linked to annoying new side effect: study

Are Sexual Side Effects Emerging With GLP-1 Agonists?

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

Increasing semaglutide dose showed very unexpected weight loss results in trials

Is Chronic Cough Another Side Effect of GLP-1 Drugs?

After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer

Questions on how new IRA drug prices will affect MFN agreements - Pharmaceutical Technology

2025 dominates for GLP-1 trial activity

Covered Most By

Media Bias Breakdown

Breaking News Topics Related to GLP-1

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PressReach

Use of Glp-1 Ras Before Pregnancy Increases the Complication Rate.

Drugs like Ozempic linked to annoying new side effect: study

Are Sexual Side Effects Emerging With GLP-1 Agonists?

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

Increasing semaglutide dose showed very unexpected weight loss results in trials

Is Chronic Cough Another Side Effect of GLP-1 Drugs?

After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer

Questions on how new IRA drug prices will affect MFN agreements - Pharmaceutical Technology

2025 dominates for GLP-1 trial activity

News about GLP-1

News about GLP-1

Covered Most By

Local News Publishers Too Big Arrow Icon

Top GLP-1 News

Study: 82% Regain Weight After Stopping Mounjaro

GLP-1 Discontinuation Associated with More Weight Gain and Pregnancy Complications

Medicare negotiates 71% discount on Novo’s Ozempic, Wegovy

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PressReach

Use of Glp-1 Ras Before Pregnancy Increases the Complication Rate.

Drugs like Ozempic linked to annoying new side effect: study

Are Sexual Side Effects Emerging With GLP-1 Agonists?

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

Increasing semaglutide dose showed very unexpected weight loss results in trials

Is Chronic Cough Another Side Effect of GLP-1 Drugs?

After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer

Questions on how new IRA drug prices will affect MFN agreements - Pharmaceutical Technology

2025 dominates for GLP-1 trial activity

Covered Most By

Media Bias Breakdown

Breaking News Topics Related to GLP-1

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PressReach

Use of Glp-1 Ras Before Pregnancy Increases the Complication Rate.

Drugs like Ozempic linked to annoying new side effect: study

Are Sexual Side Effects Emerging With GLP-1 Agonists?

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

Increasing semaglutide dose showed very unexpected weight loss results in trials

Is Chronic Cough Another Side Effect of GLP-1 Drugs?

After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer

Questions on how new IRA drug prices will affect MFN agreements - Pharmaceutical Technology

2025 dominates for GLP-1 trial activity

Local News Publishers